Helix Animation’s Post

CTAD2024 in Madrid - 2 more https://lnkd.in/emKV3S2h 1) Poster 136 on soluble TREM2 in CSF as biomarker of progress from MCI to AD https://lnkd.in/eyzsKbD4 Cerebrospinal fluid soluble TREM2 (sTREM2) is considered a possible indicator of likelihood of progress from mild cognitive impairment (MCI) to early Alzheimer's Disease (AD).  e.g.  https://lnkd.in/eg65cFki https://lnkd.in/exM9MHPK Now the Novartis group including Jennifer Sorinas Nerin, PhD and Kristin Hannesdottir and colleagues lays out that there could be a meaningful addition to use of sTREM2 by dividing CSF sTREM2 by total-tau protein levels, for identification of rapidly progressing patients. 2) Donanemab ARIA-E risk reduction strategy worked out https://lnkd.in/ey_ekjgV A specific titration regimen of donanemab, which did not affect purging of aggregated amyloid, nor reduction of tau-p(217), was identified in the context of the phase 3b study TRAILBLAZER-ALZ-6, demonstrating an ARIA-E relative risk reduction of 41%. Findings were presented as "The effect of different donanemab dosing regimens on ARIA-E and amyloid lowering in adults with early symptomatic Alzheimer disease: primary outcome results from TRAILBLAZER-ALZ 6." by an Eli Lilly team; Lilly neuroscience leader Mark Mintun linked in the NeurologyLive coverage. #CTAD #Alzheimer #TREM2 #sTREM2 #ARIA #donanemab

Ion channels are key targets for many medical treatments. In ion channel drug discovery, identifying a compound’s target specificity and conducting safety assessments are essential. ICE Bioscience provides specialized ion channel selectivity profiling panels for therapeutic profiling, risk assessment, and mechanism of action research. 🔸 Including Cardiac, Cardiovascular, Pain-Inflammation, Seizure-Convulsion, Cancer, Metabolic GI, Pulmonary-Respiratory, Neurodegeneration/Stroke, Psychiatric Disorder, Depression, and Genitourinary Channel Panels. 🔸 Techniques range from manual patch clamp to automated patch clamp and FLIPR assays. 🔸 Supported by over 100 stable cell lines, categorized into different portfolios aligned with the latest scientific insights. Explore more about our Ion channel screening services: https://lnkd.in/gim4mRYy #IonChannel #SelectivityProfilingPanels #ManualPatchClamp #AutomatedPatchClamp #FLIPR #StableCellLines #DrugDiscovery

How is iPSC technology being used to tackle one of the world's leading causes of visual impairment? At Axol Bioscience, we have over a decade of expertise unlocking iPSC technology for neuroscience and cardiovascular researchers, spanning important areas including Alzheimer's Disease, ALS and cardiotoxicity. But as iPSC leaders, we also recognize the value of human iPSCs in other therapeutic areas. Take a look at this short article where we highlight the important work being carried out by Phenocell using iPSC technology to tackle age-related macular degeneration, the leading cause of visual impairment in older people that affects around 200 million individuals. Click here to read the article: https://hubs.la/Q02ww4HX0 #iPSCs #AgeRelatedMacularDegeneration #AMD #StemCells #DrugDiscovery

Check out our new review on ALS, where we try to untangle the complex relationship between brain hyperactivity and degeneration of the motor system. This was a big collaborative effort between the preclinical and clinical worlds and we hope it helps inform future research into new therapies for those battling against ALS. https://lnkd.in/gNiVSiyj

'Integrating real-time kinetic monitoring and cell health measures into experimental workflows can assist the development and interpretation of neurological disease models that are more biologically relevant. This technology better equips researchers to expand the web of neurological disease, expedite workflow, and help in the discovery and analysis of new therapeutics.' Read the full piece from Sartorius on News Medical:

📢 Breakthrough Alzheimer's Therapy Deal Worth $21 Billion! AC Immune and Takeda have signed a deal worth $2.1 billion, giving Takeda exclusive rights to license AC Immune's ACI-24.060 therapy for Alzheimer's disease. ACI-24.060 is an active immunotherapy designed to delay or slow the progression of the disease. AC Immune will receive an upfront payment of $100 million plus milestone payments if all development milestones are achieved. Takeda will be responsible for further development, regulatory activities, and commercialization. 🤝💼🧠 #BioprocessUpdates #ACImmune #Takeda #biobucks #deal #Alzheimers #therapy #immunotherapy #diseaseprogression #milestonepayments #development #regulatoryactivities #commercialization #partnership #neuroscience #biotechnology ▷ Read the full article here: 📎 https://lnkd.in/dvrjdwd9

𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗰𝗮𝘀𝗲 𝘀𝘁𝘂𝗱𝘆 𝗼𝗻 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗳𝗼𝗿 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆. NeuroTherapia, Inc.'s Phase 1b clinical trial of NTRX-07, a new drug targeting #neuroinflammation found in Alzheimer’s Disease and other neurological diseases, has shown remarkable progress, and we are proud to have played a key role in this endeavor. Firalis Molecular Precision's involvement consisted of offering advisory support for optimizing study design and validating drug efficacy and safety. Cutting-edge technologies such as Quanterix, MESO SCALE DIAGNOSTICS, LLC., ELLA, and Luminex® were employed for comprehensive complex biomarker (such as amyloid-beta, Tau proteins, and neuroinflammation indicators) analysis. Learn more about our approach : https://lnkd.in/ebc6H5ab

📣 New product alert- the fastest and most affordable human iPSC-derived astrocytes on the market! 📣 We're delighted to announce our new axoCells™ Astrocytes line (ax0704) designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with this new axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our new axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Bolstered by our world-leading ISO 9001-accredited manufacturing processes, we are delighted to pass on further cost savings to you. Our new ax0704 astrocytes are cheaper than previous astrocytes and are priced at just £660 / $830 / €770 per vial (1 million cells)- the best price on the market! Click here to read more about this new product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02yPN8l0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02yPQHX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

I am a fan of well written lay easy to digest articles: https://lnkd.in/e3Cn96vz I am especially a fan of cross pollination and strongly believe that scientific progress in one therapeutic area can help several areas, especially the most biologically challenged ;) Neuroscience might be receiving biomarker gifts (and, of course, diagnostics and therapeutics) pretty soon!  Progress depends on clarity on what we are measuring and how we are measuring (and what are the factors that affect those two!). 

📢 Exciting News! 📚 My latest research article on Alzheimer's disease has been published! 🧠 Title: "Integrated in-silico and in-vitro assessments of HDAC6 inhibitor efficacy in mitigating amyloid beta pathology in Alzheimer’s disease" I am thrilled to announce the publication of our new research article on Alzheimer's disease, available at https://lnkd.in/duVPf47d. This achievement wouldn't have been possible without the incredible teamwork and dedication of our co-authors. Alzheimer's disease, with its devastating impact on memory and cognition, has long been a challenging puzzle in the medical field. In this study, we explored the role of HDAC6 in the regulation of neprilysin (NEP), a key enzyme in Aβ peptide degradation. With age and in sporadic Alzheimer's disease, NEP levels decrease, contributing to Aβ buildup. Our in-silico investigation of FDA-approved drugs revealed the promising interaction between Panobinostat and HDAC6. Our in-vitro experiments on the SH-SY5Y neuronal cell line validated this finding, demonstrating that Panobinostat can inhibit HDAC6, boost NEP levels, and reduce Aβ accumulation. This research suggests that Panobinostat may hold potential as a therapeutic agent for Alzheimer's, offering a novel approach to mitigating Aβ accumulation through NEP upregulation. I want to extend my heartfelt gratitude to our co-authors ( Dr manisha prajapat , Dr Gurjeet Kaur, Harvinder Singh , Dr saniya mahendiratta , Prof Bikash Medhi , Dr Ajay Prakash for their invaluable contributions, expertise, and dedication throughout this research journey. Your hard work and collaboration made this publication possible, and I look forward to further exploring the implications of our findings. Please feel free to access the full article using the DOI provided, and don't hesitate to reach out if you have any questions or insights to share. Let's continue the quest for a better understanding of Alzheimer's disease and potential treatments. Together, we can make a difference! 💪🧡 #AlzheimersResearch #Collaboration #Panobinostat #NEP #Aβ #MedicalResearch